Cipla
India - Mumbai
DIHYDROERGOTAMINE MESYLATE by Cipla is mechanism of action dihydroergotamine binds with high affinity to 5-ht 1d α and 5-ht 1d β receptors. First approved in 2024.
Drug data last refreshed 4h ago
Mechanism of Action Dihydroergotamine binds with high affinity to 5-HT 1D α and 5-HT 1D β receptors. It also binds with high affinity to serotonin 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors, noradrenaline α 2A , α 2B and α 1 receptors, and dopamine D 2L and D 3 receptors. The therapeutic activity of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
Worked on DIHYDROERGOTAMINE MESYLATE at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.